MMSI MERIT MEDICAL SYSTEMS INC
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 856982 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY9.1%
TTM net income YoY35.2%
TTM EPS YoY36.9%
Revenue 3-yr CAGR9.5%
Net income 3-yr CAGR16.9%
Margins
Gross margin49.4%
Operating margin13.5%
Net margin9.9%
FCF margin12.6%
EBITDA margin21.3%
Returns
ROE9.8%
ROA5.8%
ROIC (approx.)8.5%
Asset turnover0.58x
Leverage & solvency
Liabilities / assets40.4%
Debt / equity0.42x
Current ratio4.52x
Interest coverage6.73x
Cash quality & payout
Operating cash flow / net income1.71x
Accruals ratio-4.1%
Payout ratio—
Capex / revenue4.4%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $1.52B | $1.36B |
| Cost of revenue | $777.64M | $713.18M |
| Gross profit | $738.27M | $643.33M |
| R&D expense | $97.35M | $87.47M |
| SG&A expense | $455.21M | $399.73M |
| Operating income | $184.72M | $155.69M |
| Interest expense | $26.46M | $31.22M |
| Pretax income | $170.94M | $149.99M |
| Income tax | $42.45M | $29.64M |
| Net income | $128.49M | $120.36M |
| EBITDA | $307.89M | $258.40M |
| EPS (basic) | 2.17 | 2.07 |
| EPS (diluted) | 2.13 | 2.03 |
| Weighted avg. shares (diluted) | 60.46M | 59.37M |
| Balance sheet | ||
| Cash & equivalents | $446.40M | $378.77M |
| Receivables | $203.71M | $190.24M |
| Inventory | $333.70M | $306.06M |
| Current assets | $1.04B | $923.77M |
| PP&E, net | $428.40M | $386.17M |
| Goodwill | $506.84M | $463.51M |
| Total assets | $2.69B | $2.42B |
| Current liabilities | $239.76M | $216.40M |
| Long-term debt | $734.04M | $729.55M |
| Total debt | $734.04M | $729.55M |
| Total liabilities | $1.10B | $1.04B |
| Shareholders' equity | $1.58B | $1.38B |
| Net debt | $287.63M | $350.78M |
| Shares outstanding | 59.42M | 58.74M |
| Cash flow statement | ||
| Operating cash flow | $297.37M | $220.80M |
| Capital expenditure | $81.72M | $35.14M |
| Free cash flow | $215.66M | $185.66M |
| Investing cash flow | -$247.39M | -$368.65M |
| Financing cash flow | $16.00M | -$60.01M |
| Depreciation & amortization | $123.17M | $102.71M |
| Stock-based compensation | $43.46M | $28.47M |
Free plan shows the latest 2 periods; Pro shows all 17 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.